Open an account

Cognition Therapeutics

CGTX · NASDAQ

$0.7338+$0.0064 (+0.88%)TodayMarket closed ·
Prev close $0.7274

About CGTX

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Purchase, New York and currently employs 14 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.

Employees
14
Headquarters
Purchase, New York
Listed
Oct 8, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
cogrx.com

CGTX key statistics

Market cap
69.78M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
624.33K
Volume
461.54K
Open price
$0.73
High today
$0.758
Low today
$0.7256
52 Week high
$1.93
52 Week low
$0.5501

Cognition Therapeutics (CGTX) at a glance

As of Oct 20, 2026, Cognition Therapeutics (CGTX) shares are priced at $0.7338, giving the company a market cap of 69.78M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7256 and $0.758. The current price is 1.1% above the day's low and 3.2% below its high.

Volume so far is 461.54K shares, below the average of 624.33K shares a day.

Over the past year Cognition Therapeutics has ranged from $0.5501 to $1.93, and now sits 13% of the way up that range.

Cognition Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.04 per share against an estimate of -$0.0646.

The average analyst price target is $3.40, 363.3% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.40
Low
$3.03
Now
$0.7338
High
$4.20

CGTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 37.6% on average.

  1. Q3 FY24: reported -$0.25 per share against an estimate of -$0.2295
  2. Q4 FY24: reported -$0.17 per share against an estimate of -$0.1448
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1125
  4. Q2 FY25: reported -$0.11 per share against an estimate of -$0.1088
  5. Q3 FY25: reported -$0.06 per share against an estimate of -$0.102
  6. Q4 FY25: reported -$0.048 per share against an estimate of -$0.085
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0689
  8. Q2 FY26: reported -$0.04 per share against an estimate of -$0.0646

CGTX news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Mohd Haider

    Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data

  • Mohd Haider

    Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns

Similar companies

Companies in the same industry as Cognition Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.